Innoviva, Inc.

INVA

US45781M1018

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 22/01/2026 +03			5-day change	1st Jan Change
19.60 ^USD	+0.26%		-0.71%	-1.95%

12-13	Innoviva Gets FDA Approval for Gonorrhea Drug	DJ
12-12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Published on 12/12/2025 at 09:26 pm +03

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Innoviva, Inc.

12-13	Innoviva Gets FDA Approval for Gonorrhea Drug	DJ
12-12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
12-12	US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections	RE
12-12	Fda approved Nuzolvence (zoliflodacin) to treat uncomplicated urogenital gonorrhea	RE
11-13	Beacon Biosignals raises $86 million to accelerate AI-driven insights into brain health	RE
11-12	Beacon Biosignals, Inc. announced that it has received $86 million in funding from a group of investors	CI
11-06	Innoviva Q3 revenue up 20%, net income surges	RE
11-06	Earnings Flash (INVA) Innoviva, Inc. Reports Q3 Revenue $107.8M, vs. FactSet Est of $91.4M	MT
11-06	Innoviva, Inc. announces an Equity Buyback for $125 million worth of its shares.	CI
11-06	Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	Innoviva, Inc. authorizes a Buyback Plan.	CI
21/10/25	Antheia appoints Eric d'Esparbes as chief financial officer	RE
01/10/25	Beacon Biosignals, Inc. announced that it expects to receive $98.97489 million in funding	CI
02/09/25	Innoviva, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 01:45 PM
11/08/25	Innoviva's Specialty Therapeutics, Royalty Portfolio to Drive Outperformance, Oppenheimer Says	MT
06/08/25	Healthcare firm Innoviva posts Q2 net income	RE
06/08/25	Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $100.3M, vs. FactSet Est of $92.0M	MT
06/08/25	Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/07/25	HC Wainwright Initiates Innoviva at Buy With $40 Price Target	MT
12/06/25	Innoviva Says FDA Grants Priority Review to Zoliflodacin NDA for Treating Gonorrhea; Shares Up Pre-Bell	MT
10/06/25	Innoviva Says FDA Accepts New Drug Application for Zoliflodacin	MT
09/06/25	Innoviva, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01:20 PM
27/05/25	Syndeio Biosciences, Inc. announced that it has received $90 million in funding from a group of investors	CI
20/05/25	ZEVTERA(Ceftobiprole), An Advanced-Generation Cephalosporin Antibiotic Now Commercially Available In The U.S. To Treat Three Types Of Bacterial Infections	RE
07/05/25	Earnings Flash (INVA) INNOVIVA INC. Reports Q1 Revenue $88.6M, vs. FactSet Est of $82.7M	MT

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Employees

127

Sector

Pharmaceuticals

Calendar

03-04 - Q4 2025 Earnings Release (Projected)

More about the company